Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biofrontera AG
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics
Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
- Other Names / Subsidiaries
- Biofrontera Bioscience GmbH
- Biofrontera Development GmbH
- Biofrontera Pharma GmbH
- Cutanea Life Sciences, Inc.